Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dynavax Technologies Corporation - Common Stock (NQ:DVAX)

11.06 -0.10 (-0.90%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dynavax Technologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
JMP Securities Maintains Market Outperform Rating for Dynavax Technologies: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Dynavax Technologies (DVAX) Q4 2022 Earnings Call Transcript ↗
DVAX earnings call for the period ending December 31, 2022. 
Via The Motley Fool
News headline image
Jim Cramer On This Stock Up 2% Over 6 Months: 'You've Got A Real Winner There' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Weyerhaeuser Co (NYSE: WY) a lot. 
Via Benzinga
News headline image
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
From Clover Biopharmaceuticals
Via GlobeNewswire
News headline image
The 7 Most Undervalued Long-Term Stocks to Buy in January ↗
Investors should keep an eye on these severely undervalued long-term stocks as we get deeper into New Year 2023. 
Via InvestorPlace
News headline image
Dynavax Technologies (DVAX) Q3 2022 Earnings Call Transcript ↗
DVAX earnings call for the period ending September 30, 2022. 
Via The Motley Fool
News headline image
China-Based COVID-19 Shot Neutralizes Omicron Subvariants ↗
 
Via Benzinga
News headline image
Our 7 Top Small-Cap Stock Picks for 2023 ↗
Most of the names on this list of small-cap stock picks for 2023 are ready to rebound from a tough year in the markets. 
Via InvestorPlace
News headline image
Dynavax Adjuvant Based COVID-19 Vaccine Lowers The Risk Of Transmission ↗
 
Via Benzinga
News headline image
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
From Clover Biopharmaceuticals
Via GlobeNewswire
News headline image
Earnings Preview For Dynavax Technologies ↗
Dynavax Technologies (NASDAQ:DVAX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
3 Under-the-Radar Small-Cap Stocks With 100% Upside Potential ↗
If under-the-radar small-cap stocks are your jam, I’ve got three selections from the S&P SmallCap 600 that might be right up your alley. 
Via InvestorPlace
News headline image
Clover Provides Update on 2022 Corporate Milestones
From Clover Biopharmaceuticals
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Short Interest Sector Focus: Healthcare Sector ↗
As of the close of business on Friday, 9/23, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
News headline image
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday ↗
Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday. 
Via Benzinga
News headline image
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session ↗
Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74. 
Via Benzinga
News headline image
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Dynavax's Adjuvant Based COVID-19 Shot Shows Robust Immune Response, Safety In Younger Populations ↗
Hong Kong-listed Clover Biopharmaceuticals Ltd announced data from a global Phase 2/3 trial evaluating its COVID-19 vaccine candidate, SCB-2019, in adolescents (aged 12 to 17 years).  
Via Benzinga
News headline image
Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗
On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94. 
Via Investor's Business Daily
News headline image
Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Monday, Kura Oncology stock had its Relative Strength (RS) Rating upgraded to 91, up from 85 a day earlier. 
Via Investor's Business Daily
News headline image
Dynavax Technologies: Q2 Earnings Insights ↗
Dynavax Technologies (NASDAQ:DVAX) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings ↗
IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating ↗
Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
News headline image
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5 ↗
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
News headline image
Prometheus Biosciences Stock Shows Rising Relative Strength ↗
Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90. 
Via Investor's Business Daily
News headline image
Merus Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Thursday, Netherlands-based Merus stock had its Relative Strength (RS) Rating upgraded to 94 from 78 a day earlier. 
Via Investor's Business Daily
News headline image
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗
ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.